Cognitive dysfunction in depression: an unmet clinical need

Author/s
Muzaffer Kaser, Rashid Zaman, Barbara J. Sahakian
Citation
Issue 5 Winter 2018
CEPiP.2018.1.42-46
Abstract

Cognitive dysfunction in depression is associated with poorer clinical outcomes and interference with psychosocial functioning. However, most treatments for depression do not specifically target cognition. Neurocognitive deficits such as memory and concentration problems tend to persist after mood symptoms recover. Improving cognition in depression requires a better understanding of the brain systems implicated in depression. A comprehensive approach is warranted for refined ways to assess and treat cognitive dysfunction in depression.

Cite as: Cutting Edge Psychiatry in Practice 2018, 5(1):42-46; https://doi.org/10.65031/pwjt4950

References

  1. Marcus M, Taghi Yasamy M, van Ommeren M, Chisholm D, Saxena S. Depression a global public health concern [Internet]. World Health Organization Department of Mental Health and Substance Abuse; 2012. Available from: https://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf?ua=1 https://doi.org/10.1037/e517532013-004
  2. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, Alsuwaidan M, Baskaran A. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depression and Anxiety. 2013 Jun;30(6):515-27. https://doi.org/10.1002/da.22063
  3. Conradi HJ, Ormel J, De Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychological Medicine. 2011 Jun;41(6):1165-74. https://doi.org/10.1017/s0033291710001911
  4. Bora E, Harrison BJ, Yücel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychological Medicine. 2013 Oct;43(10):2017-26. https://doi.org/10.1017/s0033291712002085
  5. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Research. 2006 Nov 29;145(1):39-48. https://doi.org/10.1016/j.psychres.2005.11.011
  6. Majer M, Ising M, Künzel H, Binder EB, Holsboer F, Modell S, Zihl J. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychological Medicine. 2004 Nov;34(8):1453- 63. https://doi.org/10.1017/s0033291704002697
  7. Buist-Bouwman MA, Ormel J, de Graaf R, Vollebergh WA. Functioning after a major depressive episode: complete or incomplete recovery? Journal of Affective Disorders. 2004 Nov 1;82(3):363-71. https://doi.org/10.1016/j.jad.2004.02.007
  8. Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN. Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? Depression Research and Treatment. 2012;2012. https://doi.org/10.1155/2012/630206
  9. Druss BG, Schlesinger M, Allen Jr HM. Depressive symptoms, satisfaction with health care, and 2-year work outcomes in an employed population. American Journal of Psychiatry. 2001 May 1;158(5):731-4. https://doi.org/10.1176/appi.ajp.158.5.731
  10. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychological Medicine. 2014 Jul;44(10):2029-40. https://doi.org/10.1017/s0033291713002535
  11. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. Journal of Affective Disorders. 2011 Nov 1;134(1-3):20-31. https://doi.org/10.1016/j.jad.2010.11.011
  12. Gorwood P, Corruble E, Falissard B, Goodwin D Phil, F Med Sci GM. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. American Journal of Psychiatry. 2008 Jun;165(6):731-9. https://doi.org/10.1176/appi.ajp.2008.07040574
  13. Kessing LV. Cognitive impairment in the euthymic phase of affective disorder. Psychological Medicine. 1998 Sep;28(5):1027-38. https://doi.org/10.1017/s0033291798006862
  14. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? Journal of Neurology, Neurosurgery & Psychiatry. 2004 Dec 1;75(12):1662-6. https://doi.org/10.1136/jnnp.2003.031773
  15. Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology. 2010 Jul 6;75(1):27-34. https://doi.org/10.1212/wnl.0b013e3181e62124
  16. Exploring Cognitive Dysfunction in People with Depression [Internet]. Clark Health Communications; 2015. Available from: https://www.comresglobal.com/wp-content/uploads/2015/09/Clark-Health-Communications_ Cognitive-Dysfunction-in-Depression.pdf      
  17. Keefe RS, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. The Journal of Clinical Psychiatry. 2014 Aug;75(8):864-76. https://doi.org/10.4088/jcp.13r08609
  18. Shilyansky C, Williams LM, Gyurak A, Harris A, Usherwood T, Etkin A. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. The Lancet Psychiatry. 2016 May 1;3(5):425-35. https://doi.org/10.1016/s2215-0366(16)00012-2
  19. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology. 2012 Jul 1;27(4):215-23. https://doi.org/10.1097/yic.0b013e3283542457
  20. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology. 2014 Oct 1;17(10):1557-67. https://doi.org/10.1017/s1461145714000546
  21. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015 Jul;40(8):2025. https://doi.org/10.1038/npp.2015.52
  22. Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sanchez C, Fischer CW. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. Journal of Pharmacology and Experimental Therapeutics. 2012 Mar 1;340(3):666-75. https://doi.org/10.1124/jpet.111.189068
  23. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. Journal of Clinical Psychopharmacology. 2004 Feb 1;24(1):87-90. https://doi.org/10.1097/01.jcp.0000104910.75206.b9
  24. Kaser M, Deakin JB, Michael A, Zapata C, Bansal R, Ryan D, Cormack F, Rowe JB, Sahakian BJ. Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2017 Mar 1;2(2):115-22. https://doi.org/10.1016/j.bpsc.2016.11.009
  25. Scoriels L, Jones PB, Sahakian BJ. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology. 2013 Jan 1;64:168-84. https://doi.org/10.1016/j.neuropharm.2012.07.011
  26. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry. 2013 Jan 1;74(11):1101-7. https://doi.org/10.4088/jcp.13r08560
  27. Müller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology. 2013 Jan 1;64:490-5. https://doi.org/10.1016/j.neuropharm.2012.07.009
  28. Harmer D Phil CJ, O’Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, Goodwin D Phil, FRC Psych GM, Cowen PJ. Effect of acute antidepressant administration on negative affective bias in depressed patients. American Journal of Psychiatry. 2009 Oct;166(10):1178-84. https://doi.org/10.1176/appi.ajp.2009.09020149
  29. Roiser JP, Elliott R, Sahakian BJ. Cognitive mechanisms of treatment in depression. Neuropsychopharmacology. 2012 Jan;37(1):117. https://doi.org/10.1038/npp.2011.183
  30. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature Reviews Immunology. 2016 Jan;16(1):22. https://doi.org/10.1038/nri.2015.5
  31. Tang MM, Lin WJ, Pan YQ, Guan XT, Li YC. Hippocampal neurogenesis dysfunction linked to depressive-like behaviors in a neuroinflammation induced model of depression. Physiology & Behavior. 2016 Jul 1;161:166-73. https://doi.org/10.1016/j.physbeh.2016.04.034
  32. Gimeno D, Kivimäki M, Brunner EJ, Elovainio M, De Vogli R, Steptoe A, Kumari M, Lowe GD, Rumley A, Marmot MG, Ferrie JE. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychological Medicine. 2009 Mar;39(3):413-23. https://doi.org/10.1017/s0033291708003723
  33. Chang HH, Lee IH, Gean PW, Lee SY, Chi MH, Yang YK, Lu RB, Chen PS. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain, Behavior and Immunity. 2012 Jan 1;26(1):90-5. https://doi.org/10.1016/j.bbi.2011.07.239
  34. Khandaker GM, Oltean BP, Kaser M, Dibben CR, Ramana R, Jadon DR, Dantzer R, Coles AJ, Lewis G, Jones PB. Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJ Open. 2018 Sep 1;8(9):e025333. https://doi.org/10.1136/bmjopen-2018-025333
  35. National Academies of Sciences, Engineering, and Medicine. Enabling discovery, development, and translation of treatments for cognitive dysfunction in depression: Workshop summary. National Academies Press; 2015 Oct 29. https://doi.org/10.17226/21745
  36. Cullen B, Nicholl BI, Mackay DF, Martin D, Ul-Haq Z, McIntosh A, Gallacher J, Deary IJ, Pell JP, Evans JJ, Smith DJ. Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants. European Psychiatry. 2015 Nov 1;30(8):950-8. https://doi.org/10.1016/j.eurpsy.2015.08.006
  37. 37. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scandinavian Journal of Public Health. 2012 Aug;40(6):505-15. https://doi.org/10.1177/1403494812456637
  38. Lewis G, Kounali DZ, Button KS, Duffy L, Wiles NJ, Munafo MR, Harmer CJ, Lewis G. Variation in the recall of socially rewarding information and depressive symptom severity: a prospective cohort study. Acta Psychiatrica Scandinavica. 2017 May;135(5):489-98. https://doi.org/10.1111/acps.12729